Vanguard Portfolio Management’s Acadia Pharmaceuticals ACAD Stock Holding History
Bought
Maintained
Sold
Other funds holding ACAD
BBA
Vanguard Portfolio Management's ACAD Position: Q3 2026 in Review
Vanguard Portfolio Management increased its Acadia Pharmaceuticals (ACAD) stake by 7% in Q3 2026, buying an estimated $16.6M and bringing the position to 9,457,124 shares worth $191M. The position accounts for 0.01% of the portfolio, ranked #1204.
Vanguard Portfolio Management first reported a position in ACAD in Q1 2026 and has held it in 3 quarters since. The position peaked at $224M in Q2 2026. 350 funds tracked by Wall St. Rank hold ACAD as of Q3 2026.
- Vanguard Portfolio Management held 9,457,124 shares of Acadia Pharmaceuticals worth $191M as of Q3 2026.
- Vanguard Portfolio Management bought 618,674 Acadia Pharmaceuticals shares in Q3 2026, an estimated $16.6M.
- Acadia Pharmaceuticals made up 0.01% of Vanguard Portfolio Management's portfolio in Q3 2026, its #1204 holding.
- Vanguard Portfolio Management first reported a position in Acadia Pharmaceuticals in Q1 2026 and has held it in 3 quarters since.
- Vanguard Portfolio Management's Acadia Pharmaceuticals position peaked at $224M in Q2 2026.
- 350 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2026.
Based on Vanguard Portfolio Management's 13F filing for Q3 2026, filed 13 Nov 2026.